Oral Minoxidil Bone Health and Density Impact

What the Hair-Loss Studies Measured

The research behind low-dose oral minoxidil for hair loss reports hair outcomes, blood pressure and cardiovascular side effects. A 2021 review of 17 studies with 634 patients found oral minoxidil effective and well tolerated in healthy patients who struggle with topical use, and called for larger randomized dose-comparison studies [5]. A 2021 safety study of 1,404 patients treated for at least three months reported hypertrichosis in 15.1%, lightheadedness in 1.7%, fluid retention in 1.3% and tachycardia in 0.9% [4]. A 2025 meta-analysis of low-dose oral minoxidil found no significant change in systolic or diastolic blood pressure and a heart rate increase of 2.67 beats per minute [6]. None of these papers reported bone density or fracture outcomes.

What the Minoxidil Tablet Label Says About Bone

The minoxidil tablet label is written for hypertension that is symptomatic or associated with target-organ damage and not manageable with a diuretic plus two other antihypertensives [1]. It states that using minoxidil tablets, in any formulation, to promote hair growth is not an approved indication, so hair-loss use of oral minoxidil is off-label [1].

Bone appears once, under altered laboratory findings: alkaline phosphatase increased varyingly without other evidence of liver or bone abnormality [1]. That is a laboratory note, not a measure of bone mineral density.

The 2018 Sinclair Combination Study

A 2018 observational pilot by Sinclair followed 100 women with pattern hair loss given a once-daily capsule containing minoxidil 0.25 mg plus spironolactone 25 mg for 12 months [7]. Hair loss severity score fell by 0.85 at 6 months and 1.3 at 12 months, shedding score fell by 2.3 and 2.6, and mean blood pressure fell by 4.52 mmHg systolic and 6.48 mmHg diastolic; eight women had side effects, generally mild [7]. The study reported hair-loss, shedding, blood-pressure and adverse-effect findings, not bone density or fracture outcomes, and both drugs were given together in the same capsule [7].

Other Safety Findings Reported

At the low doses used for hair loss, the systemic effects reported in the 1,404-patient study were lightheadedness, fluid retention and tachycardia [4]. At antihypertensive doses the label warns of salt and water retention with reversible edema in about 10% of non-dialysis patients, pericardial effusion in about 3% of treated patients who were not on dialysis, and tachycardia with worsening angina, and it carries a boxed warning for pericardial effusion that can progress to tamponade [1]. None of these are bone effects.

The Short Answer

Minoxidil is a direct-acting peripheral arteriolar vasodilator that lowers blood pressure by reducing peripheral vascular resistance [1]. Neither the tablet label nor the low-dose hair-loss studies report bone-loss outcomes. The label's only bone-related statement is that alkaline phosphatase increased variably without other evidence of liver or bone abnormality [1].